Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2017 March;61(1) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2017 March;61(1):108-14

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Publication history
Estratti
Per citare questo articolo

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Rivista di Medicina Nucleare e Imaging Molecolare


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,481


eTOC

 

ORIGINAL ARTICLE  


The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2017 March;61(1):108-14

DOI: 10.23736/S1824-4785.16.02727-8

Copyright © 2014 EDIZIONI MINERVA MEDICA

lingua: Inglese

Stable metabolic disease on FDG-PET provides information on response to endocrine therapy for breast cancer

Vibeke KRUSE 1, Christophe VAN DE WIELE 2, 3, Alex MAES 3, 4, Marleen BORMS 5, Hans POTTEL 4, Simon VAN BELLE 1, Veronique COCQUYT 1

1 Department of Medical Oncology, Ghent University Hospital, Ghent, Belgium; 2 Department of Radiology and Nuclear Medicine, University of Ghent, Ghent, Belgium; 3 Department of Nuclear Medicine, Groeninge University Hospital, Kortrijk, Belgium; 4 Subfaculty of Medicine, Catholic University of Leuven, Kortrijk, Belgium; 5 Department of Radiotherapy and Medical Oncology, Groeninge University Hospital, Kortrijk, Belgium


PDF  


BACKGROUND: The aim of this study was to assess whether outcome in advanced breast cancer patients is related to metabolic response to endocrine therapy determined by fluorodeoxyglucose positron-emission tomography (FDG-PET).
METHODS: We retrospectively identified 21 consecutive breast cancer patients receiving endocrine therapy for metastatic disease (mean number of previous therapies 3.6±3.5). All patients had been evaluated with at least 2 FDG-PETs. The first scan was performed by initiation of endocrine therapy. The second scan was performed after a mean of 3.8±1.14 months. Seventy-two FDG-avid lesions were identified and followed. The mean change in SUVmax (ΔSUVmax) was calculated per patient.
RESULTS: ΔSUVmax dichotomized using the group median as cut-off (8.6%) was predictive of progression-free survival (PFS). The median PFS for the response-group (N.=10, median ΔSUVmax -20.9%) was 10.1 months. The median PFS for the progressive disease-group (N.=11, median ΔSUVmax 40.6%) was 6.7 months (log-rank testing P=0.033).
CONCLUSIONS: Our data suggest that breast cancer patients under hormonal therapy with stable disease on FDG-PET have a longer PFS when compared to non-responders. This finding is new, supporting the value of endocrine therapy among patients with advanced breast cancer.


KEY WORDS: Hormone replacement therapy - Breast neoplasms - Fluorodeoxyglucose F18 - Positron-emission tomography - Disease-free survival

inizio pagina

Publication History

Issue published online: January 5, 2017
Article first published online: October 7, 2014
Manuscript accepted: October 3, 2014
Manuscript revised: September 12, 2014
Manuscript received: April 29, 2014

Per citare questo articolo

Kruse V, Van de Wiele C, Maes A, Borms M, Pottel H, Van Belle S, et al. Stable metabolic disease on FDG-PET provides information on response to endocrine therapy for breast cancer. Q J Nucl Med Mol Imaging 2017;61:108-14. DOI: 10.23736/S1824-4785.16.02727-8

Corresponding author e-mail

vibeke.kruse@uzgent.be